Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Combination treatment improves progression-free survival in patients with advanced urothelial cancer

Combination treatment improves progression-free survival in patients with advanced urothelial cancer

Two new treatments may benefit patients with high risk prostate cancer, trial shows

Two new treatments may benefit patients with high risk prostate cancer, trial shows

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Researchers use mathematical modeling to find effective chemotherapy treatments for cancer patients

Researchers use mathematical modeling to find effective chemotherapy treatments for cancer patients

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients

New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients

Cancer experts to discuss novel treatment strategies at ESMO Asia 2016 Congress

Cancer experts to discuss novel treatment strategies at ESMO Asia 2016 Congress

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Researchers focus on optimal use of immune agents in frontline setting for NSCLC treatment

Researchers focus on optimal use of immune agents in frontline setting for NSCLC treatment

NUS researchers identify molecular switch that makes breast cancer cells more aggressive

NUS researchers identify molecular switch that makes breast cancer cells more aggressive

Bioactive compound from neem plant shows promising effects on prostate cancer

Bioactive compound from neem plant shows promising effects on prostate cancer

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Added benefit of lung cancer drug not proven, says IQWiG

Added benefit of lung cancer drug not proven, says IQWiG

Bioengineers develop 2-in-1 nanomedicine for treating cancer

Bioengineers develop 2-in-1 nanomedicine for treating cancer

NaF-PET/CT scans can accurately detect bone metastases in advanced prostate cancer patients

NaF-PET/CT scans can accurately detect bone metastases in advanced prostate cancer patients

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients